Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Nektar Therapeutics (NKTR) is trading at $42.22, down 3.12% on the day. Its market value of $1.44B makes it the 2998th largest of the 3132 companies we follow.
It is close to the bottom of its 52-week range ($33.40 to $109.00), 61.3% under the high.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
NKTR is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Quote as of Oct 6, 2026 4:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,131 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$42.22 is the latest print for NKTR, a move of -3.12% against yesterday's close of $43.58. Today's low and high so far: $41.35 and $43.50.
Equity value comes to $1.44B at the current price. By that measure it is number 2998 of the 3132 names in our coverage.
The year's floor is $33.40 and the ceiling $109.00. Shares are 61.3% away from that ceiling.
Our data shows no dividend paid by Nektar Therapeutics over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on NKTR.